3rd World ADC Asia Brochure

SAVE $300 BY
June 25-27, 2024 | Incheon, South Korea REGISTERING

www.worldadc-asia.com BEFORE
WELCOME
APRIL 26
3rdANNUAL
EXPERT SPEAKERS
ASIA 2024
Trailblazing Innovation &

Collaborations in ADC Drug
AGENDA
Development in Asia
Expert Speakers Include:
PARTNER WITH US
Ziping Wei Yasuyuki Kaneta Jun Ge
Chief Executive Senior Director Executive Director,
Officer Daiichi Sankyo Head of China
Bliss Biopharma Clinical Development
Gilead
Tse Wen Chang Sun-Hwa Lee Heidi Wang

Founder & Chairman Vice Chief Scientific Chief Executive
Immunwork Officer Officer
Novelty Nobility OBI Pharma
REGISTER YOUR PLACE
Lead Partner Partners
+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Antibody Drug Conjugates World ADC Event Series @World_ADC #WorldADC
World ADC Insights Coming Closer
to the Growing ADC Community June 25-27, 2024
WELCOME
Incheon, South Korea
Based in Asia
Why Your Peers Are
Looking Forward to the
The year 2024 has been considered the ‘coming of age’ era for antibody-drug conjugates, Conference:
in great part due to the remarkable resurgence in drug development across the Asia-
Pacific region. The massive increase in the quantity of new ADC programs from Asian
Having a chance to meet
developers has been especially noticeable since 2022, with the number of ADCs in the with like-minded colleagues
clinic surpassing those being developed the United States for the fifth year in a row. This, in the industry to discuss
alongside multiple high-profile deals in the region, is making all eyes turn towards Asia ADC drug development is
for the next blockbuster ADC. rare. We look forward to
EXPERT SPEAKERS
Returning by popular demand after a short break, the 3rd World ADC Asia will engaging, be invigorated and
be bringing together pioneers and key opinion leaders across mega-pharma and inspired
biotechnology focusing on China, Japan, Taiwan, South Korea and Singapore this
June.
Heidi Wang, Chief Executive
Officer, OBI Pharma
There has never been a stronger time for antibody-drug conjugate development in Asia.
This is shown by the Japanese born Enhertu reaching blockbuster status, Asia accounting I am excited to be part of
for half of the new ADC clinical trials in 2023, and some of the biggest ADC deals this meeting to learn about
occurring across APAC. Join the ADC community based in this region to discuss the
the latest advancements
most pressing Asian-specific challenges, learn from recent innovations, and meet
long-standing experts from the west to create partnerships that can propel your ADC and innovations in the field
further than ever before. of ADC, to network with
peers, particularly in Asia,
Be in the room when the east meets the west across three packed days with the highest
-quality industry speakers including Daiichi Sankyo, Eisai, Shanghai Miracogen, and to share our research
PinotBio, Orum Therapeutics, Pfizer, and more. Backed by 14 years of experience and insights
providing insights to the global ADC community, World ADC will connect you with those Mike Liao, Global Clinical
AGENDA
leading the way in innovation.
Pharmacology Lead –
Whether you are a CEO, Managing Director, Head of Lab, or Scientist, this is the meeting Oncology, Genentech
for you to get the most up to date knowledge about what is happening with ADCs in Asia.
KEY BENEFITS OF ATTENDING
Gain a Learn about novel Navigate varying Understand the Explore the PARTNER WITH US
comprehensive innovation in ADC governing development of importance of
overview of technologies guidance to DXd technology revolutionary
clinical updates coming out of Asia ensure regulatory and the conjugation
and main such as “CHO- harmonization to latest clinical technology in
aspects of clinical TEM”, bispecific gain IND approval developments of CMC development
development in ADCs, stroma and kickstart your early DXd assets to improve
China, as well targeting ADCs, clinical trials with with Daiichi manufacturing
REGISTER YOUR PLACE
as the future novel targets OBI Pharma Sankyo process with

opportunities being explored, Genequantum
and challenges and more with Healthcare
that await ADC Immunwork, ABL
developers with Bio and Inxmed
Gilead

2
Asia: The Upcoming Hotspot
for ADC Innovation
June 25-27, 2024
WELCOME
With the constant deals, innovations and collaborations With ADC news dominating the headlines, it might be
in the space, all eyes are turning towards Asia for the hard to keep track of all the new developments. This
next big thing when it comes to ADC development. By is your executive summary illustrating the existing
breaking through the biosimilars and looking towards opportunities and current state of the ADC Asian Market,
novel payloads, conjugation technologies, linkers, and most recent news. Brought closer to your home, the 3rd
more this region of the world is leading the charge on World ADC Asia is your industry touchpoint to discuss
EXPERT SPEAKERS
antibody-drug conjugate innovation. novel technolgies, understand regulatory guidance, hone
strategic collaborations, and most importantly, accelerate
the development of the next asian-based approved ADC.
Geographic Distribution of 2023 New Preclinical ADCs

Geographic Distribution of the ADCs Entered the Clinic by Main by Main Developers’ Headquarters
Developers' Headquarters 70
60 60
Asia Europe United States
50 50
Number of Drugs
40
40
Number of Drugs
30
30
20
AGENDA
20 10
0
10
United States
China
South Korea
Singapore
Japan |
India
United Kingdom
Germany
Switzerland
Netherlands
Denmark
Italy
Spain
Czech Republic
France
0
97
00
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
19
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
North America Asia Europe
Top 6 Pieces of News to Summarize 2023: The Year of ADCs
PARTNER WITH US
Everyone wants Daiichi Sankyo Samsung Eisai’s cancer Ajinomoto and JPM23:
an ADC: GSK and Merck Biologics moves drug Halaven Exelixis partner Samsung
up plans to open
pays US$85M announce global its US$1.5B+
at the center of to develop novel plans to kick
upfront for development plant. The CDMO US$2B pact with antibody-drug off antibody-
ex-China rights and commer- also has plans Bliss Bio, like conjugates drug conjugate
to Hansoh cialization to expand its its Bristol Myers for cancer manufacturing in
Pharma’s collaboration antibody-drug ADC deal treatment early 2024
conjugates
antibody-drug for three Daiichi business by
(May 2023) (Jan 2023) (Jan 2023)
conjugate Sankyo Dxd building an ADC
REGISTER YOUR PLACE
(Oct 2023) ADCs facility by 2024,

(Oct 2023) after announcing
an investment
in ADC-aligned
biotech Araris
Biotech at the
beginning of 2023
(June 2023)

3
Your Expert Speakers
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Jinwon Jung Dohyun Nam Jia He

Senior Director Chairman Senior Research Analyst
ABL Bio Aimed Bio Beacon Targeted
Therapies
Shanshan Xu Mingjiu Chen Ziping Wei

Vice President, External Chief Executive Officer Chief Executive Officer
Innovations Biosion Bliss Biopharma
BioNTech
EXPERT SPEAKERS
Dhiraj Gambhire Yasuyuki Kaneta Masayuki Miyano
Executive Director, Senior Director Principal Scientist
Global Clinical Daiichi Sankyo Eisai
Development
Daiichi Sankyo
Mike Liao Paul Song Amy Que

Global Clinical Chief Scientific Officer Chief Technology Officer
Pharmacaology Lead - Genequantum Genequantum
Oncology Healthcare Healthcare
Genentech
Jun Ge Shan Yongqiang Gary Khoo

Executive Director, General Manager, Global Vice President CMC
Head of China Clinical Innovation Center Hummingbird
Development Henlius Biotech Bioscience
Gilead
AGENDA
Tse Wen Chang Zaiqi Wang Stephen Slocum
Founder & Chairman Chief Executive Officer Director of Drug Development
Immunwork Inxmed LegoChem Biosciences
Lei Zhu Sun-Hwa Lee Heidi Wang

Senior Director Vice Chief Chief Executive Officer
Mersana Therapeutics Scientific Officer OBI Pharma
Novelty Nobility
PARTNER WITH US
James Palacino Vivian Trang Hyun Yong Cho
Senior Vice President & Principal Scientist Chief Scientific Officer
Head of Research Pfizer PinotBio
Orum Therapeutics
Amy Han Nitin Damle Mary Chaohong Hu

Executive Director Executive Vice President & Independent
Regeneron Chief Innovation Officer Consultant
Pharmaceuticals Sun Pharma Advanced
Research Company
Ziye Sui Hsing-Mao Chu Steven Kan

Chief Executive Officer Chief Executive Officer Chief Executive Officer
REGISTER YOUR PLACE
Shanghai Miracogen/ T-E Meds Thousand Oaks

Lepu Biopharma Biologics
Jangsoon Lee Seung-Jae Myung

Associate Professor, Chief Executive Officer
Director Preclinical Core EDIS Biotech
University of Hawaii
Cancer Center

4
Pre-Conference Workshop Day
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Tuesday | June 25, 2024

Coffee & Check-In 8.00
Workshop A 9.00
Navigating Varying Regulatory Guidance to Inform ADC Clinical

Studies & Meet Global Regulatory Requirements
EXPERT SPEAKERS
The biggest roadblock in developing ADCs in Asia is not having enough Workshop Leaders
regulatory guidance from other agencies. This is especially important when trying
Heidi Wang
to run clinical trials in multiple countries while adhering to varying regulatory guidelines. Chief Executive
This interactive session will give you a holistic overview of varying governmental Officer
regulations and how to follow them to confidently meet expectations from agencies. OBI Pharma
Join this workshop to:
• Understand how to jump over regulatory hurdles in the APAC region
• Examine the differing regulatory requirements of the FDA, EMA, NMPA, and more Dhiraj Gambhire
• Assess the best way to gain IND approval to kickstart your clinical trials Executive Director,
Global Clinical
• Analyze regulatory expectations from a CMC aspect Development
• Focus on regulatory harmonization across the globe Daiichi Sankyo
Lunch Break & Networking 12.00
AGENDA
Workshop B 1.00
Navigating Strategic Collaborations to Make a Mark in the ADC World

Numerous high-profile collaborations in Asia have propelled the scope of innovation Workshop Leaders
in the region. Thus, partnering with external companies has become a strategic
decision to increase your footing in the field. This interactive session will answer key Mary Chaohong
collaborations questions to help you navigate the partnership landscape and foster strong Hu
relationships especially with mega pharma. Independent
Consultant
PARTNER WITH US
Join this workshop to:
• Understand how global partnerships can open up global rights for development and
commercialization
• Evaluate what makes a company a good partner- is it an ADC in the clinic? Novel Paul Song
propriety technology? Chief Scientific
Officer
• Determine the potential bigger pharma have and what value you can bring to the table
Genequantum
• Navigate different cultures and ways of working to harbor stronger relationships Healthcare
• Enhance communication with mega pharma
Shanshan Xu
Vice President,
External
REGISTER YOUR PLACE
Innovations
BioNTech
End of Pre-Conference Workshop Day 4.00

5
Scientific Program Day One
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Wednesday | June 26, 2024
7.00 Coffee & Check-In
Tse Wen Chang

Founder & Chairman 7.50 Chair’s Opening Remarks
Immunwork
EXPERT SPEAKERS
Outlining Clinical Updates & Clinical Progression in Field to Ensure a Smooth Translation
Into the Clinic
Jun Ge 8.00 Exploring the Clinical Development of ADCs in China to Understand

Executive Director, Progress in the Region
Head of China Clinical • Review a brief history and progress of ADCs to date
Development • Discuss clinical development of ADCs around the world and in China
Gilead • Look into the future: opportunities and challenges
8.30 Exploring the Clinical Results of MRG003 & MRG004A to Develop EFGR
Ziye Sui Targeted ADCs
Chief Executive Officer • Comprehensive review of five ADCs currently in clinical studies
Shanghai Miracogen/ • Outline updated clinical results on nasopharyngeal carcinoma and HNSCC for MRG003,
Lepu Biopharma an EGFR targeted ADC
• Gain a clinical update for MRG004A, a TF targeted ADC
AGENDA
9.00 From Product to Platform: Henlius’ Practices & Progress in ADC to
Shan Yongqiang Address Unmet Medical Needs
General Manager,
Global Innovation • Review how ADC is a strategic R&D field of Henlius based on its 13+ year antibody
Centre capabilities and integrated R&D platform
Henlius Biotech • Explore the highlights of ADC assets’ progress in clinical and pre-clinical stages
• Learn how Henlius is dedicated in building ADC platform - “Hanjugator”
9:30 Leveraging Linker Design & Drug Developability Assessment to Develop

Successful ADCs
• Explore how ADC linkers represent more than a bridge between the antibody and
payload, allowing to modulate ADCs’ biological activity
PARTNER WITH US
• Discuss how identifying the best combination of antibody, linker and payload is a
challenge that can be overcome by applying stage-specific evaluation criteria to de-risk
ADC candidate selection
• Review case studies showing how to construct and evaluate appropriate ADC candidate
matrices, varying payloads, and linker elements for lead candidate selection
10.00 Morning Break & Speed Networking

This session is an opportunity to connect with peers and hold in-depth conversations with
some of the brightest minds in the ADC field to establish meaningful and lasting
relationships.
Honing Novel Innovations in ADC Technologies Coming Out of Asia to Establish

Competitive Differentiation
REGISTER YOUR PLACE
11.00 Exploring ADCs With Site-Specific Conjugation, DAR of 8 or 12, & Payloads
With Dual Drugs to Turbocharge ADC Innovation
Hsing-Mao Chu • Discuss the “CHO-TEM” technology, combining CHO Pharma’s “glycan modification”
Chief Executive Officer technology, and T-E Meds’ “drug bundles” technology
T-E Meds • Outline how antibody molecule glycans are modified with one enzyme to create 4 azido
groups, to which 4 drug bundles each with 2 or 3 drugs of two categories are linked
• Learn how to produce homogeneous ADCs with high DAR (8 or 12), and dual drugs

6
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
11.30 Analyzing the Benefits of First-in-Class Stroma Targeting ADC

Zaiqi Wang • Learn how high stroma is a key mechanism leading to resistance in hard-to-treat tumors
Chief Executive Officer • Assess an innovative target that was identified on tumor stroma
Inxmed • Discuss how a stroma-targeting ADC demonstrates strong in vivo efficacy and deepens
responses of cancer cell targeting ADC
EXPERT SPEAKERS
12.00 Addressing the Complexity of Manufacturing ADCs From Early Stage to
Commercial
• Outlining key challenges related to breakthrough and fast approval designation
• Discussing methods to build a robust technical package to support a consistent
regulatory strategy
• Delivering important updates on conjugation and fill-finish capacity
12.30 Networking Lunch
1.30 Exploring the Advantages of Using Bispecific ADCs & Their Impact on
Jinwon Jung Efficacy & Toxicity to Increase Patient Treatability
Senior Director • Discuss proof of concept study of a bispecific ADC
ABL Bio • Review the recent development progress of a bispecific ADC
• Assess the benefit of bispecific ADC in terms of efficacy and toxicity
AGENDA
2.00 Reviewing the Development of DXd ADC Technology & the Latest
Clinical Results
Yasuyuki Kaneta
Senior Director • Gain an overview of the DXd-ADC technology platform
Daiichi Sankyo • Receive updates on clinical development of T-DXd
• Discuss updates on preclinical and clinical development of early DXd assets, such as
R-DXd, DS-3939, etc.
2.30 Exploring the OBI Pharma ADC Assets & the GlycOBI™ Platform
• Discover how OBI Pharma has developed a unique glycan ADC platform (GlycOBI™) to
enable a site-specific conjugation, which is in a ‘Plug and Play’ format and compatible
Heidi Wang
with any antibodies, linkers, and payloads in various DAR
PARTNER WITH US
Chief Executive Officer
OBI Pharma • Review how assets using the GlycOBI™ platform have the potential for improved in vivo
efficacy, better safety profile, and enhanced stability in animal studies
• Share data about how Anti-Nectin-4, -TROP2, HER2, and bi-specific ADCs were
developed based on OBI’s GlycOBI™ platform
3.00 ADC: Process, Manufacturing, & Quality (CMC)

• Providing an overview of the development history, mechanism of action, and future
Steven Kan
direction of ADC products
Thousand Oaks • Highlighting the key considerations in the process development and scale-up production
Biologics of ADC products, including bare antibodies, drug substance (DS), and drug product (DP)
• Exploring the comprehensive quality management strategy and essential research
methods for assessing the key quality attributes of ADC products
REGISTER YOUR PLACE
3.30 Afternoon Networking Break & Scientific Poster Session

This is an informal session to help you connect with your peers in a relaxed atmosphere
and continue forging new and beneficial relationships. You will have the opportunity to
present your work, and review presentations displaying novel approaches and findings.

7
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
4.30 Development of Eribulin-based Antibody-Drug Conjugates

Ziping Wei
Chief Executive Officer • Introduction of Eribulin-based ADC BB-1701 and BB-1705
Bliss Biopharma • Discussion of preclinical results of Eribulin-based ADCs
• Progress of BB-1701 phase 1/2 clinical development
EXPERT SPEAKERS
Exploring Global Manufacturing Capabilities & the Challenges With Antibody & Linker-
Payload Supply Chain to Reduce Process Complexity & Standardize ADC Development
5.00 Panel Discussion: Mastering Supply Chain Issues in Sourcing Antibodies, Linkers & Payloads to Asia to
Plan Ahead & Reduce Lead Times
• Understanding why supply chain is a bigger problem in the APAC region
• Dealing with a different time zone: the pros and cons
• Navigating the difficulty of accessing the European and American markets
Jangsoon Lee Gary Khoo Lei Zhu

Associate Professor, Director Vice President CMC Senior Director
Preclinical Core Hummingbird Bioscience Mersana Therapeutics
University of Hawaii Cancer
Center
Amy Que 5.30 Empowering Revolutionary Conjugation Technology Into CMC
AGENDA
Chief Technology Development & GMP Manufacturing of ADC Therapeutics
Officer • Discuss integrated conjugation manufacturing platform
Genequantum • Review a continuous conjugation manufacturing process
Healthcare • Outline a quality control strategy
Mingjiu Chen
Chief Executive Officer 6.00 Chair’s Closing Remarks
Biosion
PARTNER WITH US
6.15 End of Scientific Program Day One
World ADC Asia Summit can provide me with the

opportunity to meet and have discussions with world-
class researchers and get insights for
developing better ADCs
REGISTER YOUR PLACE
Hyun Young Cho, Chief Scientific Officer,

Pinotbio

8
Scientific Program Day Two
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Thursday | June 27, 2024
7.00 Coffee & Check-In
Nitin Damle
Executive Vice
President & Chief
Innovation Officer Chair’s Opening Remarks
EXPERT SPEAKERS
7.50
Sun Pharma
Advanced Research
Company
Identifying Novel Targets & Their Benefits to Diversify ADC Programs & Design a More
Accurate ADC
8.00 Unmet Needs in ADCs for Gastrointestinal Cancer: East-West Differences &
Seung-Jae Myung Novel Target Strategies Beyond HER2 & TROP2
Chief Executive Officer • Addressing the unmet needs of ADCs in gastrointestinal cancers
EDIS Biotech • Discussing the regional differences in the need for an ADC for gastrointestinal cancers
• Going beyond HER2 and TROP2: Novel targets for ADCs in gastrointestinal cancers
8.30 Developing a Precise ADC for Novel Targets to Take Your ADC From Bench
AGENDA
Do-Hyun Nam to Bedside
Chairman • Exploring target discovery for ADCs
Aimed Bio • Understanding pre-clinical and clinical translation
• Developing the best-in-class ADC for precision oncology
9.00 SGN-B6A: A Vedotin Antibody-Drug Conjugate that Targets Integrin Beta-6

& Shows Clinical Efficacy in Multiple Solid Tumor Indications
Vivian Trang
Principal Scientist • Explore how SGN-B6A is an investigational, first-in-class ADC, which shows high
Pfizer specificity towards integrin beta-6
• Overview of SGN-B6A preclinical and clinical safety and efficacy data
• Discuss the rationale for clinical combination between SGN-B6A and CPIs
PARTNER WITH US
9.30 Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP®
Technology
• AJICAP®️ Conjugation: Examining how site-specific technologies are being employed
in many of the next-generation ADCs due to the enhancement of clinically relevant
biological properties observed in various preclinical studies
• AJICAP®️ Linker: Demonstrating a novel hydrophilic linker technology that enables the
versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
• Showcasing Bispecific and Trispecific antibodies produced by fully-chemical
conjugation technology
10.00 Morning Networking Break

REGISTER YOUR PLACE
11.00 NN3201, a Novel C-Kit Targeting ADC, Exhibits Robust Preclinical Anti-
Sun-Hwa Lee Tumor Efficacy in SCLC & GIST Models
Vice Chief Scientific
Officer • Navigating the effects of NN3201 in small cell lung cancer
Novelty Nobility • Exploring a novel C-Kit targeting ADC
• Showing anti-tumor efficacy in SCLC and GIST models

9
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Innovating Novel Linker & Payload Technologies

to Increase Stability, Efficiency & Patient Treatability
11.30 Delivery of BET Protein Degrader to Pancreatic Cancer & Their
Masayuki Miyano Microenvironment Via CEACAM6-Targeted Antibody–Drug Conjugate
Principal Scientist • Analyzing Antibody protein degrader conjugate
Eisai
EXPERT SPEAKERS
• Understanding pancreatic cancer and its effects
• Reviewing a novel payload, BET protein degrader
12.00 From Concept to Market: Accelerating ADC Development With WuXi XDC’s
Fully Integrated Discovery & CMC Platforms
• Showcasing the one-stop integrated discovery service platform focusing on bioconjugate
lead selection that includes mAb/protein generation, payload linker synthesis,
bioconjugate preparation, in vitro and in vivo characterization
• Demonstrating fully integrated ADC CMC development and manufacturing with industry
leading DNA to IND timeline of 15 months; mAb/payload-linker/conjugation DS & DP all by
in-house team and facilities
• Sharing vast ADC experience with 250+ discovery projects, 75+ CMC projects, 27+ INDs
12.30 Networking Lunch
Jia He 1.30 A Flourishing ADC space

Senior Research
AGENDA
• Review of the current ADC landscape, both clinical and preclinical
Analyst
Beacon Targeted • Deep dive into the characteristics of ADCs in each stage of development
Therapies • Analyze trends on the recent flurry of ADC deals
2.00 Exploring Next-Generation ADC Development From Payload & Linker

Hyun Yong Cho Perspective to Drive ADC Performance & Innovation
Chief Scientific Officer • Explore a new Topoisomerase 1 inhibitor
Pinotbio • Discuss a new linker system for ADC
• Review how it had better performance than Enhertu
2.30 Analyzing the Advantages of Protein Homeostasis by Dual Precision

James Palacino Approach
Senior Vice-President
PARTNER WITH US
& Head of Research • Discover the development of a novel, catalytic payload class
Orum Therapeutics • Explore diversity of degrader SAR while also enabling conjugation
• Improve potency and selectivity of delivery to target cells
Stephen Slocum
Director of Drug
Development 3.00 Talk Reserved for LegoChem Biosciences
LegoChem
Biosciences
3.30 Afternoon Networking Break

REGISTER YOUR PLACE
Maximizing Therapeutic Window to Increase Efficacy & Reduce Off-Target Toxicity of ADC
4.00 PEG-Based Bispecific ADC: Better Tumor Penetration, Wider Therapeutic
Shumin(Sam) Liu Window
Shenzhen Enduring • Assessing how it provides better tumor penetration
Biotech • Discussing how there were not any Fc related toxicities
• Exploring how it has a wider therapeutic window

10
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
4.30 Effective PK/PD Translational Strategies to Enable a Successful Early

Mike Liao Clinical Development
Global Clinical • Defining the translational PK/PD considerations for ADC FIH starting dose prediction
Pharmacology Lead - • Integrating nonclinical knowledge through computational modeling and simulations to
Oncology inform Phase I design dose escalations
Genentech • Exploring translational PK/PD data to support model-informed clinical safety mitigation
EXPERT SPEAKERS
strategy, drug-drug interaction risks
5.00 Understanding How Therapeutic Window Differs From Patient to Patient to

Amy Han Incorporate Individual Therapy & Find the Maximum Tolerable Dose
Executive Director • Navigating varying patient immune responses
Regeneron • Using differing immune responses to individualize therapy
• Evaluating the benefits of individualized therapy
5.30 Chair’s Closing Remarks
AGENDA
5.40 End of Conference
PARTNER WITH US
East Asia has been very active in ADC research and
development; I am very interested to meet up other ADC
researchers and companies in Asia
Tse-Wen Chang, Founder Chairman, Immunwork
REGISTER YOUR PLACE

11
Partner With Us
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Your Asian-Dedicated Platform to Showcase Your Exclusive ADC

Services & Foster New Relationships in the Region
Even though Asian ADC developers are on their A-game right now, outsourcing their ADC manufacturing,
carrying out in-depth analysis, finding the right equipment and more is holding them back. Whether it is
the language barriers, biologics, or small molecule sourcing problems, the challenges they are facing are
pressing and they are seeking service providers to solve them.
The 3rd World ADC Asia is the fastest and best opportunity to connect with a highly engaged
audience of Asian-wide drug developers, and highlight how easy these roadblocks can be overcome with
EXPERT SPEAKERS
your offerings.
Top Three Reasons to Partner:
Position Yourself as the Network With Local Industry Showcase Your

Go to Service Provider for Experts & Boots-on-the- Best-In-Class Services
Asian Companies Ground Scientists
Our audience does not always
While Asia is leading the charge Bringing both experts and know who they best service
on novel innovations, the majority newcomers in the same room, providers are in other parts of the
of drug developers face the same this is your chance to speed world and what they can offer.
AGENDA
problem: they need a reliable up relationship building with Use this conference to ensure
service provider to help them key decision makers as well your services are key players in
with their ADC manufacturing as scientists that are using your the region.
needs. services daily.
Partner with us to ensure you are the company they think of when Asian-based drug developers outsourcing
ADC manufacturing. Get in touch today!
SENIORITY OF ATTENDEES* GEO BREAKDOWN

CxO- 10% 5%
80%
PARTNER WITH US
15%
Asia
Director- 40%
North
America
President/Vice President- 5% Europe
Head/Manager- 15%
Professor- 10%
Scientist- 5%
Other- 15% *Statistics Taken from Previous Event

REGISTER YOUR PLACE
GET INVOLVED
Rob Keast Matt Ashman
Partnerships Director Partnerships Director
Tel: +1 617 455 4188 Tel: +1 617 455 4188
Email: sponsor@hansonwade.com Email: sponsor@hansonwade.com

12
Partners
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Abzena
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing
sites in the US. Abzena’s complimentary services and technologies in chemistry, biology
and manufacturing, are applied to the selection, development and manufacture of better
biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies
and academic groups all over the world and is focused on enabling the development of better
EXPERT SPEAKERS
treatments for patients. Abzena’s technologies have enabled many of its customers to progress
products through to clinical development. Abzena was created through the incorporation of
Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom
now trade as Abzena.
www.abzena.com
BSP Pharmaceuticals
BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer
drugs with high potency and cytotoxitc characteristics for the Pharmaceuticals Industry. BSP has
been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP
with investments in new technologies and production methods in a high containment plant.
www.bsppharmaceuticals.com
AGENDA
Thousand Oaks Biologics
Thousand Oaks Biologics (TOBio) is a leading CDMO specializing in the development and
manufacturing of biologics. TOBio offers CMC in antibody-drug conjugates, monoclonal
antibodies, and other recombinant protein products. The state-of-the-art GMP facilities at the
Shanghai ADC site include bioreactors, purification equipment, and fill-finish lines. TOBio’s
comprehensive quality management system ensures compliance with ICH, US FDA, EU EMA,
and China NMPA standards. With a proven track record of successful project delivery, including
over 100 clinical – stage projects and 3 pre-Approval inspections, TOBio is a trusted global
CDMO for biopharmaceutical companies.
PARTNER WITH US
www.tobiopharm.com
Ajinomoto Biopharma Services

Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and
biologics production, from process development and cGMP manufacturing to aseptic fill finish,
including cytotoxics. As a global CDMO, they provide the adaptive solutions, responsive service,
trusted partnership and peace of mind you’ve come to rely on.
www.ajibio-pharma.com
REGISTER YOUR PLACE

13
Partners
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
WuXi XDC
WuXi XDC, a subsidiary of WuXi Biologics, is a leading global contract research, development
and manufacturing organization (CRDMO) focused on antibody drug conjugates (ADC) and the
broader bioconjugate market. The company’s end-to-end services cover antibody intermediates
and other biologics, chemical payloads and linkers, as well as bioconjugated drug substance
and drug product from concept to commercialization. WuXi XDC has been successful in bringing
multiple ADC projects to the Investigational New Drug (IND) filing stage in record time, nearly
EXPERT SPEAKERS
cutting in half the traditional development timeline.
www.wuxixdc.com
OminAb
OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse
antibody repertoires and high-throughput screening technologies to enable discovery of next-
generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI)
of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse®
that have been genetically modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic®
(transgenic chicken) address industry needs for bispecific antibody applications though a
common light chain approach, and OmniTaur™ features unique structural attributes of cow
antibodies for complex targets. We believe the OmniAb animals comprise the most diverse
AGENDA
host systems available in the industry and they are optimally leveraged through computational
antigen design and immunization methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with custom algorithms to identify
fully human antibodies with superior performance and developability characteristics. These
proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico
tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various
technologies and capabilities. Additionally, an established core competency focused on ion
channels and transporters further differentiates OmniAb’s technology and creates opportunities
in many emerging target classes. OmniAb antibodies have been leveraged across modalities,
including bispecific antibodies, antibody-drug conjugates and others.
PARTNER WITH US
The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge
antibody discovery and optimization offering a highly efficient and customizable end-to-end
solution for the growing discovery needs of the global pharmaceutical industry.
www.omniab.com
Samsung Biologics
Samsung Biologics is a fully integrated CDMO partner of choice, providing highly tailored
solutions to clients while meeting the evolving needs of the global healthcare industry. With
proven regulatory approvals, we provide seamless offerings from cell-line development to final
fill/finish at every stage for biopharmaceutical products. Our plants are cGMP compliant with a
REGISTER YOUR PLACE
wide range of bioreactor scales to serve varying client needs and meet growing market demand.
We hold a total capacity of 604KL at Bio Campus I, the world’s largest biomanufacturing site,
and have announced plans to construct a fifth plant, which will be operational in 2025.
partner.samsungbiologics.com

14
Exhibitors
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Asymbio
AsymBio is the emerging business unit of Asymchem Group striving to become a
technology-driven, fully-empowered one-stop CDMO services platform for biologic (mAb,
ADC, plamsid&mRNA), offering customized services with outstanding quality and efficient
performance. We have built an integrated and comprehensive CDMO service platform for
ADC drugs (payload-linker, mAb, conjugation), which including but not limited to development,
manufacturing, quality control and regulatory affairs. Our one-stop ADC CDMO service platform
is able to efficiently empower ADCs.
EXPERT SPEAKERS
www.asymbio.com
Cytiva
Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader
dedicated to helping customers discover and commercialize the next generation of therapeutics.
We bring dedicated technical expertise and a broad portfolio of tools, technologies, and services
that enable the development, manufacture, and delivery of transformative medicines to patients.
www.cytivalifesciences.com/en/us
Aton Bio
Aton Biotech is a fast-growing CDMO company which is committed to enabling new biological
drugs for clients with an integrated bio-pharmaceutical platform. Our service ranges from cell line
development to clinical and end-to-end CDMO commercial manufacturing services, including
AGENDA
development of mammalian expressed monoclonal antibodies, fusion proteins, bispecific
antibodies, ADC, etc.
www.atonbio.com
Axplora
Axplora, created from the merger of Farmabios, Novasep and PharmaZell, is a leading API
manufacturing partner to the world’s leading pharmaceutical and biotechnology companies,
delivering top quality active ingredients on time and at scale, to the highest industry standards.
Axplora is dedicated to helping pharmaceutical companies make critical medicines better, faster,
safely, reliably, and sustainably benefitting patients worldwide.
PARTNER WITH US
The group provides unique services for the development, fast-track, clinical supply and
commercial cGMP manufacture of ADCs including the payload-linker and the bioconjugation,
leveraging its in-house purification expertise, HPAPI culture & state-of-the art cGMP conjugation
facilities. We offer a full and flexible range of ADC manufacturing services with hand-run
experience on different conjugation platforms.
www.axplora.com
PROVEO
Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete
supply chain solution for Antibody Drug Conjugates (ADCs).
REGISTER YOUR PLACE
Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class
solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl
mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of
the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and
commercial projects.
www.proveoadc.com

15
Exhibitors
3rdANNUAL
ASIA 2024
WELCOME
June 25-27, 2024
Sterling Pharma Solutions

Sterling Pharma Solutions is a global contract development and manufacturing organisation
(CDMO), with 50 years’ experience in small molecule API development and manufacturing
services. In April 2021 Sterling acquired ADC Bio, a UK based biotechnology company specialising
in antibody drug conjugates and bioconjugation. Together, as Sterling Pharma Solutions, the
teams have developed an integrated service offering for existing and potential customers, which
combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise.
Sterling has four facilities employing more than 800 people: its HQ in Dudley, Northumberland,
EXPERT SPEAKERS
UK; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in
the US, in Cary, North Carolina and Germantown, Wisconsin.
www.sterlingpharmasolutions.com
Levena
LEVENA is headquartered in Suzhou, China and has R&D centers and GMP manufacturing sites in
Nanjing and San Diego, with a total of about 20,000m2 of R&D and GMP manufacturing sites, covering
antibody, drug-linker, conjugation and lyophilization. Aimed to truly realize the one-stop service of
ADC. As a leading enterprise of Antibody-drug conjugate (ADC), LEVENA has been committed to the
development and industrialization of ADC. The company has the world’s leading new generation of site-
specific conjugation technology and a number of conjugate-related patents. At present, the company
has a mature and professional core technology platform, covering the research and development
and production of highly efficacious toxins (including Duostatins (Tubulin inhibitors), Duomycins (DNA
alkylating agents), and Camptothecins), and various site-specific conjugation methods (K-Lock,
C-Lock,C-Lock DXD and High DAR low toxicity platform). Based on this, it has carried out extensive
AGENDA
cooperation with domestic and foreign pharmaceutical companies in the research and development
of new drugs. LEVENA’s patent platform has achieved all-round coverage from low toxicity high DAR
to high toxicity low DAR. Can meet the diverse needs of different requirements. At the same time,
based on the flexible application of platform technology, LEVENA can realize customized drug-linker
recommendation for specific projects and needs, help quickly and efficiently screen out the best pre-
clinical candidate ADC, and accelerate the whole project cycle.
www.levenabiopharma.com/cn/home
Levena
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable,
PARTNER WITH US
and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases,
and ophthalmic diseases. Up to date, 5 products have been launched in China, 2 have been approved for
marketing in overseas markets, 19 indications are approved worldwide, and 7 marketing applications have
been accepted for review in China, the U.S., and the EU, respectively. Since its inception in 2010, Henlius
has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation
embedded throughout the whole product life cycle including R&D, manufacturing and commercialization.
It has established global innovation centers and Shanghai-based manufacturing facilities in line with
global Good Manufacturing Practice (GMP), including Xuhui Facility and Songjiang First Plant, both
certificated by China and the EU GMP.Henlius has pro-actively built a diversified and high-quality product
pipeline covering over 50 molecules and has continued to explore immuno-oncology combination
therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched
products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for
injection, trade name in Europe: Zercepac®), the first China-developed mAb biosimilar approved both
in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative
REGISTER YOUR PLACE
product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours,
squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC),
and esophageal squamous cell carcinoma (ESCC), making it the world’s first anti-PD-1 mAb for the
first-line treatment of SCLC. What’s more, Henlius has conducted over 30 clinical studies for 16 products,
expanding its presence in major markets as well as emerging markets.
www.henlius.com/en/Index.html

16
Ready to Register? Network with key leaders in the
space facing similar challenges when
it comes to breaking through the
WELCOME
biosimilars trend
Explore novel targets, linker
chemistries, payloads and more to
lead the charge in innovation
3 Easy Ways to Book
Navigate strategic collaborations
to improve global partnerships and
www.worldadc-asia.com/take-part/register increase communication with mega
pharma
Tel: +1 617 455 4188
EXPERT SPEAKERS
Email: adc@hansonwade.com
Drug Developer Pricing Register & Pay by Friday, April 26 Final Price
Conference + Pre-Conference
$1,747 (Save $300) $2,047
Workshop Day
Conference Only $1,249 (Save $300) $1,549
Academic Pricing Register & Pay by Friday, April 26 Final Price

$1,547 (Save $300) $1,847
Workshop Day
AGENDA
Solution Provider Pricing Register & Pay by Friday, April 26 Final Price
$4,597 (Save $300) $5,097
Workshop Day
*All presentations will be in English

* All prices shown in USD
To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email adc@hansonwade.com
**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email adc@hansonwade.com Do you work for a
Not-for-Profit organization? Email us at adc@hansonwade.com to inquire about attending
PARTNER WITH US
Team Discounts** **Please note that discounts are only valid when three or more
delegates from one company book and pay at the same time.
• 10% discount – 3 Attendees Discounts cannot be used in conjunction with any other offer or
discount. Only one discount offer may be applied to the current
• 15% discount – 4 Attendees pricing rate.
Contact: register@hansonwade.com
• 20% discount – 5 + Attendees
Venue
Grand Hyatt Incheon
208 Yeongjonghaeannam-ro 321beon-gil, Jung-gu,
REGISTER YOUR PLACE
www.hyatt.com/en-US/hotel/south-korea/grand-hyatt-incheon/inche?
TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Changes to Conference & Agenda: Every reasonable effort will be made to Data Protection: The personal information shown and/or provided by you will be
Cancellations must be received in writing. If the cancellation is received more adhere to the event programme as advertised. However, it may be necessary held in a database. It may be used to keep you up to date with developments
than 14 days before the conference attendees will receive a full credit to a future to alter the advertised content, speakers, date, timing, format and/or location in your industry. Sometimes your details may be obtained or made available
conference. Cancellations received 14 days or less (including the fourteenth of the event. We reserve the right to amend or cancel any event at any time. to third parties for marketing purposes. If you do not wish your details to be
day) prior to the conference will be liable for the full fee. A substitution from the Hanson Wade is not responsible for any loss or damage or costs incurred as used for this purpose, please write to: Database Manager, Hanson Wade Ltd,
same organization can be made at any time. a result of substitution, alteration, postponement or cancellation of an event for Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom
any reason and including causes beyond its control including without limitation,
acts of God, natural disasters, sabotage, accident, trade or industrial disputes,
terrorism or hostilities.

17

3rd World ADC Asia Brochure

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

3rd World ADC Asia Brochure

Uploaded by

Copyright:

Available Formats

SAVE $300 BY

June 25-27, 2024 | Incheon, South Korea REGISTERING

Trailblazing Innovation &

Expert Speakers Include:

Tse Wen Chang Sun-Hwa Lee Heidi Wang

Lead Partner Partners

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

KEY BENEFITS OF ATTENDING

as the future novel targets OBI Pharma Sankyo process with

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Geographic Distribution of 2023 New Preclinical ADCs

North America Asia Europe

Top 6 Pieces of News to Summarize 2023: The Year of ADCs

(Oct 2023) ADCs facility by 2024,

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Jinwon Jung Dohyun Nam Jia He

Shanshan Xu Mingjiu Chen Ziping Wei

Mike Liao Paul Song Amy Que

Jun Ge Shan Yongqiang Gary Khoo

Lei Zhu Sun-Hwa Lee Heidi Wang

Amy Han Nitin Damle Mary Chaohong Hu

Ziye Sui Hsing-Mao Chu Steven Kan

Shanghai Miracogen/ T-E Meds Thousand Oaks

Jangsoon Lee Seung-Jae Myung

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Tuesday | June 25, 2024

Navigating Varying Regulatory Guidance to Inform ADC Clinical

Lunch Break & Networking 12.00

Navigating Strategic Collaborations to Make a Mark in the ADC World

End of Pre-Conference Workshop Day 4.00

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Wednesday | June 26, 2024

7.00 Coffee & Check-In

Tse Wen Chang

Jun Ge 8.00 Exploring the Clinical Development of ADCs in China to Understand

9:30 Leveraging Linker Design & Drug Developability Assessment to Develop

10.00 Morning Break & Speed Networking

Honing Novel Innovations in ADC Technologies Coming Out of Asia to Establish

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Wednesday | June 26, 2024

11.30 Analyzing the Benefits of First-in-Class Stroma Targeting ADC

12.30 Networking Lunch

3.00 ADC: Process, Manufacturing, & Quality (CMC)

3.30 Afternoon Networking Break & Scientific Poster Session

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Wednesday | June 26, 2024

4.30 Development of Eribulin-based Antibody-Drug Conjugates

Jangsoon Lee Gary Khoo Lei Zhu

Amy Que 5.30 Empowering Revolutionary Conjugation Technology Into CMC

World ADC Asia Summit can provide me with the

Hyun Young Cho, Chief Scientific Officer,

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Thursday | June 27, 2024

7.00 Coffee & Check-In

9.00 SGN-B6A: A Vedotin Antibody-Drug Conjugate that Targets Integrin Beta-6

10.00 Morning Networking Break

+1 617 455 4188 @ adc@hansonwade.com www.worldadc-asia.com

Thursday | June 27, 2024

Innovating Novel Linker & Payload Technologies

12.30 Networking Lunch

Jia He 1.30 A Flourishing ADC space

2.00 Exploring Next-Generation ADC Development From Payload & Linker

2.30 Analyzing the Advantages of Protein Homeostasis by Dual Precision

3.30 Afternoon Networking Break